Novo Nordisk A/S shares advanced after the drugmaker’s blockbuster weight-loss drug Wegovy received US approval to treat a ...

US FDA approves Novo Nordisk’s Wegovy to treat metabolic dysfunction-associated steatohepatitis: Bagsværd, Denmark Monday, August 18, 2025, 11:00 Hrs [IST] Novo Nordisk, a lead ...

Eli Lilly is a leader in the market for GLP-1 medicines. The company's Zepbound, indicated for weight loss, is racking up ...

Novo Nordisk (NVO) stock in focus as the company wins FDA accelerated nod for weight loss therapy Wegovy against the liver ...

Novo Nordisk said on Friday the U.S. Food and Drug Administration has granted accelerated approval for its weight-loss drug ...

Novo Nordisk’s obesity drug Wegovy was cleared by U.S. regulators to treat an increasingly common liver disease, MASH.

The new approval allows the GLP-1 to be used to treat adults with the liver disease metabolic dysfunction-associated steatohepatitis (MASH) and liver scarring. Wegovy is the first GLP-1 to receive ...

Novo Nordisk A/S’s blockbuster weight-loss drug Wegovy received Food and Drug Administration approval to treat a serious form ...

Novo Nordisk (NVO) announced that the US Food and Drug Administration has approved an additional indication for Wegovy based ...

A growing wave of lawsuits is targeting Novo Nordisk, the manufacturer of the widely used drugs Ozempic and Wegovy, following ...

Hims & Hers shares fall after a report says the FTC has investigated its cancellation policies and billing practices for over ...